Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rosiglitazone.

B J Goldstein1

  • 1Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College, Philadelphia, PA 19107, USA.

International Journal of Clinical Practice
|August 24, 2000
PubMed
Summary
This summary is machine-generated.

Rosiglitazone, a new oral antidiabetic drug, effectively lowers blood sugar in type 2 diabetes patients. It demonstrates a favorable safety profile with low liver abnormality incidence, unlike troglitazone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.

Clinical pharmacology and therapeutics·2016
Same author

Letters to the editors.

Journal of general internal medicine·2016
Same author

Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.

Diabetes, obesity & metabolism·2015
Same author

Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.

Current medical research and opinion·2015
Same author

A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.

International journal of clinical practice·2015
Same author

Primary objective of study of sitagliptin in patients with ESRD on dialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2013
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Rosiglitazone is a potent thiazolidinedione oral antidiabetic agent.
  • It exhibits greater PPAR gamma binding affinity and antihyperglycaemic potency than pioglitazone and troglitazone in preclinical models.

Purpose of the Study:

  • To evaluate the safety and efficacy of rosiglitazone in patients with type 2 diabetes.
  • To compare the safety profile of rosiglitazone with troglitazone, particularly regarding hepatotoxicity.

Main Methods:

  • Clinical data analysis from over 4500 patients with type 2 diabetes.
  • Assessment of efficacy through reductions in hemoglobin A1c and fasting plasma glucose.
  • Evaluation of safety through patient-years of exposure and incidence of liver abnormalities.

Main Results:

Related Experiment Videos

  • Rosiglitazone significantly reduces hemoglobin A1c and fasting plasma glucose in monotherapy and combination therapy.
  • A low incidence of liver abnormalities was observed in over 3500 patient-years of exposure.
  • No significant food or drug interactions were reported.

Conclusions:

  • Rosiglitazone is a safe and effective oral antidiabetic agent for type 2 diabetes.
  • It presents a favorable safety profile, especially concerning liver function, compared to troglitazone.
  • Rosiglitazone is a valuable therapeutic option, particularly as first-line therapy.